News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

480 Biomedical Announces Initial Observations From OCT Sub-Study of the STANCE Trial Evaluating the First Self-Expanding Bioresorbable Scaffold for Superficial Femoral Artery Disease


10/10/2012 10:00:11 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--480 Biomedical announced today that the first twenty-five patients enrolled in its STANCE trial have been successfully implanted with the company’s fully self-expanding, bioresorbable scaffold. Dr. Andrew Holden presented data highlighting the STANCE trial’s pioneering use of Optical Coherence Tomography (OCT) to prospectively evaluate the performance of 480 Biomedical’s Stanza™ SFA scaffold. The presentation was delivered at the Late-Breaking Clinical Trials session of the 10th Annual Vascular InterVentional Advances (VIVA) Meeting.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES